AI-based digital pathology models have been qualified by regulators for endpoint determination in MASH trials, with additional AI risk models and large language models applied to patient enrollment, recruitment and retention.
Published September 16, 2026, this narrative review examines how AI is being applied to metabolic dysfunction-associated steatohepatitis trials, a field where only resmetirom and semaglutide had received conditional approval at the time of writing.
- Impact 30%
- 49
- Evidence 25%
- 95
- Scale 20%
- 35
- Confidence 15%
- 87
- Recency 10%
- 95
Updated Sep 18, 2026 · TRV-2026-1134
ace